‘That’s A Much Broader Statement’: Hikma Grilled In Amarin Vascepa Skinny-Label Appeal
Hikma Faces Stern Words As Amarin Looks To Revive Induced Infringement Dismissal
Hikma may have succeeded in dismissing Amarin’s induced infringement claim against the firm over Hikma’s skinny label generic Vascepa in the US, but a panel of judges for the US Court of Appeals for the Federal Circuit challenged that the generics manufacturer’s public disclosures “sound like an actual statement, encouraging use for the broad sweep of things: that this generic can be used instead of the brand, without any narrowing.”
